VIGL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	70 848.00
Gjennomsnittsvolum	87 275.00
Markedsverdi	113.88M
EPS	$0 ( 2024-03-26 )
Neste inntjeningsdato	( $-0.600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.420
ATR14	$0.0210 (0.69%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Kaufmann Petra	Buy	330 000	Stock Option Grant (Right to Buy)
2024-03-18	Kaufmann Petra	Buy	0
2024-03-01	Booth Bruce	Buy	34 612	Stock Option Grant (Right to Buy)
2024-03-01	Bruhn Suzanne Louise	Buy	24 073	Stock Option Grant (Right to Buy)
2024-03-01	Blanchard Cheryl R	Buy	24 761	Stock Option Grant (Right to Buy)

INSIDER POWER
99.98
Last 93 transactions
Buy: 32 103 135 \| Sell: 31 582 660

Volum Korrelasjon

Lang: 0.09 (neutral)

Kort: 0.20 (neutral)

Signal:(64.774) Neutral

Vigil Neuroscience, Inc. Korrelasjon

10 Mest positive korrelasjoner
RMRM	0.816

10 Mest negative korrelasjoner
NETE	-0.824
SHSP	-0.81
IMRA	-0.803
BOCH	-0.801

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Vigil Neuroscience, Inc. Korrelasjon - Valuta/Råvare

0.82
( strong )

0.62
( weak )

0.00
( neutral )

0.47
( neutral )

-0.84
( strong negative )

Vigil Neuroscience, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-399 000 (0.00 %)
EPS:	$-2.13

FY	2023
Omsetning:	$0
Bruttogevinst:	$-399 000 (0.00 %)
EPS:	$-2.13

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.01M (0.00 %)
EPS:	$-2.14

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.531

Financial Reports:

No articles found.

Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Sanntidsoppdatering for Vigil Neuroscience, Inc. [VIGL]

Upcoming Earnings Alert